title: Childhood amblyopia: current management and new trends.
abstract: With a prevalence of 2-5%, amblyopia is the most common vision deficit in children in the UK and the second most common cause of functional low vision in children in low-income countries.
  
  
  
  Pubmed, Cochrane library and clinical trial registries (clinicaltrials.gov, ISRCTN, UKCRN portfolio database).
  
  
  
  Screening and treatment at the age of 4-5 years are cost efficient and clinically effective. Optical treatment (glasses) alone can improve visual acuity, with residual amblyopia treated by part-time occlusion or pharmacological blurring of the better-seeing eye. Treatment after the end of the conventional 'critical period' can improve vision, but in strabismic amblyopia carries a low risk of double vision.
  
  
  
  It is not clear whether earlier vision screening would be cost efficient and associated with better outcomes. Optimization of treatment by individualized patching regimes or early start of occlusion, and novel binocular treatment approaches may enhance adherence to treatment, provide better outcomes and shorten treatment duration.
  
  
  
  Binocular treatments for amblyopia.
  
  
  
  Impact of amblyopia on education and quality of life; optimal screening timing and tests; optimal administration of conventional treatments; development of child-friendly, effective and safe binocular treatments.
authors.affiliation: NIHR Biomedical Research Centre at Moorfields Eye Hospital, London, UK UCL Institute of Ophthalmology, London, UK.
authors.forename: Vijay
authors.initials: V
authors.lastname: Tailor
authors.affiliation: UCL Institute of Ophthalmology, London, UK.
authors.forename: Manuela
authors.initials: M
authors.lastname: Bossi
authors.affiliation: Experimental Psychology, University College London, London, UK.
authors.forename: John A
authors.initials: JA
authors.lastname: Greenwood
authors.affiliation: NIHR Biomedical Research Centre at Moorfields Eye Hospital, London, UK UCL Institute of Ophthalmology, London, UK annegret.dahlmann-noor@moorfields.nhs.uk.
authors.forename: Annegret
authors.initials: A
authors.lastname: Dahlmann-Noor
mesh_terms: D000550:Amblyopia / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D002648:Child; D003362:Cost-Benefit Analysis; D042241:Early Diagnosis; D005139:Eyeglasses; D006801:Humans; D008403:Mass Screening / Q000191:economics / Q000458:organization & administration*; D015995:Prevalence; D011788:Quality of Life; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology
keywords: amblyopia*/diagnosis; amblyopia*/therapy; child; humans; treatment outcome; vision screening; visual acuity